---
title: "aTyr Pharma, Inc. (ATYR.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/ATYR.US.md"
symbol: "ATYR.US"
name: "aTyr Pharma, Inc."
industry: "生物技術"
---

# aTyr Pharma, Inc. (ATYR.US)

| Item | Detail |
|------|--------|
| Industry | 生物技術 |
| Location | 美股市場 |
| Website | [atyrpharma.com](https://atyrpharma.com) |

## Company Profile

aTyr Pharma, Inc.是一家臨床階段的生物技術公司，專注于發現和開發將 tRNA 合成酶生物學轉化為針對美國纖維化和炎症的新療法的產品候選者。其主要治療候選藥物是 efzofitimod，一種選擇性 NRP2 調節劑，目前正在進行針對肺肉芽腫病的三期臨床試驗；同時也在進行針對其他間質性肺病（ILDs）的 1b/2a 期臨床試驗，如慢性過敏性肺炎和與結締組織疾病相關的 ILD。該公司正在開發 ATYR0101，這是一種源自天冬氨酸-tRNA 合成酶的融合蛋白，目前處于針對纖維化的臨床前開發階段；以及 ATYR0750，這是一種源自丙氨酸-tRNA 合成酶的蛋白，用于治療肝臟疾病。該公...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-27T04:30:18.000Z

**Overall: D (0.71)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 279 / 402 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -19.15% |  |
| Net Profit YoY | -17.72% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.21 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 97.01M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 190000.00 |  |


**Multi Score**: D

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -103.22% | E |
| Profit Margin | -39537.89% | E |
| Gross Margin | -11547.37% | E |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -19.15% | E |
| Net Profit YoY | -17.72% | D |
| Total Assets YoY | 16.41% | A |
| Net Assets YoY | 22.88% | A |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -0.25% | D |
| OCF YoY | -19.15% | E |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.00 | E |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 24.95% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - aTyr Pharma, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-103.22%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-39537.89%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-11547.37%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-19.15%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-17.72%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "16.41%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "22.88%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-0.25%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-19.15%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "24.95%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ADMA生物制藥 (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | Rigel制藥 (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.29 | 207/602 | - | - | - |
| PB | 1.21 | 102/602 | 6.26 | 3.79 | 0.95 |
| PS (TTM) | 510.56 | 290/602 | 1194.86 | 1194.86 | 406.03 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-04T05:00:00.000Z

Total Analysts: **10**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 10% |
| Overweight | 2 | 20% |
| Hold | 7 | 70% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.99 |
| Highest Target | 20.00 |
| Lowest Target | 1.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/ATYR.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/ATYR.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/ATYR.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.